Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 120

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 120
---
 
 of the total number of authorized directors;                                                                                       |

| ● | a requirement that no member                                                                                                                  
 of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required         
 by law and subject to the rights of the holders of any series of preferred stock to elect additional directors under specified circumstances, 
 upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election             
 of directors;                                                                                                                                 |

<div align='center'>62</div>

| ● | a requirement of approval                                                                                                                
 of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific 
 provisions of our Charter; and                                                                                                           |

| ● | the authority of the board                                                                                                           
 of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred 
 stock may include rights superior to the rights of the holders of Common Stock.                                                      |

In addition, because we
are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which may prohibit certain business
combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions
in our Charter or Bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors
or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or
proxy contest. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect
directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction
or changes in our board of directors could cause the market price of our Common Stock to decline.

If we engage in future acquisitions or strategic partnerships, this may increase capital requirements, dilute stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

We intend to evaluate various
acquisition opportunities and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights,
technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:

| ● | increased operating expenses 
 and cash requirements;       |

| ● | the assumption of additional            
 indebtedness or contingent liabilities; |

| ● | the issuance of our equity